Hagiwara Satoru, Nishida Naoshi, Chishina Hirokazu, Ida Hiroshi, Sakurai Toshiharu, Komeda Yoriaki, Kitano Masayuki, Kudo Masatoshi
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan.
Intern Med. 2016;55(22):3273-3277. doi: 10.2169/internalmedicine.55.7035. Epub 2016 Nov 15.
The patient was a 67-year-old female with liver cirrhosis due to hepatitis C. She was administered furosemide at 20 mg/day and spironolactone at 25 mg/day, but the ascites did not improve. Despite the additional administration of tolvaptan at 3.75 mg/day, the response to ascites was still poor. While the dose of tolvaptan was thereafter increased to 7.5 mg/day on the 7th hospital day, the ascites still persisted. However, she continued to receive tolvaptan (7.5 mg/day) because the worsening of her subjective symptoms was mild and she wished to do so. The ascites was later found to have almost completely disappeared on computed tomography (CT) at 6 months.
该患者为一名67岁女性,因丙型肝炎导致肝硬化。她每天服用20毫克呋塞米和25毫克螺内酯,但腹水并未改善。尽管每天额外服用3.75毫克托伐普坦,对腹水的反应仍然不佳。此后在住院第7天,托伐普坦剂量增加至7.5毫克/天,但腹水仍然存在。然而,由于她的主观症状恶化较轻且她希望继续服用,所以她继续接受托伐普坦治疗(7.5毫克/天)。6个月后,计算机断层扫描(CT)显示腹水几乎完全消失。